Ventana to Collaborate with Boehringer Ingelheim on Companion Diagnostic Tests

Ventana Medical Systems, Inc. (VMSI; Tucson, AZ, USA), a member of the Roche Group, and Boehringer Ingelheim (BI; Ingelheim, Germany) will collaborate on the development of companion diagnostic tests for Boehringer Ingelheim oncology programs. Ventana will utilize its immunohistochemistry technology platform, experience, and expertise in companion diagnostic development and premarket approval (PMA) submissions to support Boehringer Ingelheim's personalized medicine healthcare strategies for cancer drug development.

Together with Roche, VMSI is driving personalized healthcare through accelerated drug discovery and the development of "companion diagnostics" to identify the patients most likely to respond favorably to specific therapies. By integrating the development of companion diagnostic kits and drug candidates, Boehringer Ingelheim strives to yield cancer treatments with optimized benefit risk profiles. In addition to Boehringer Ingelheim, VMSI has worked with more than 45 biopharmaceutical partners over the past decade and is currently engaged in over 150 collaborative projects to develop and commercialize companion diagnostics globally.

Ventana Medical Systems, Inc., a member of the Roche Group, manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. Ventana solutions are used in clinical histology and drug development-research laboratories worldwide. The company's integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to reduce errors, support diagnosis, and inform treatment decisions for anatomic pathology professionals. Together with Roche, VMSI is driving personalized healthcare through accelerated drug discovery and the development of "companion diagnostics" to identify the patients most likely to respond favorably to specific therapies.

The Boehringer Ingelheim group is a family-owned company that has been committed to researching, developing, manufacturing, and marketing medications of high therapeutic value for human and veterinary medicine. In 2012, Boehringer Ingelheim achieved net sales of about USD 19.1 billion. R&D expenditure in the business area prescription medicines corresponds to 22.5% of its net sales.

Related Links:
Ventana Medical Systems, Inc
Boehringer Ingelheim